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Abstract
Studies in experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis, have shown
that B cells markedly influence the course of the disease, although whether their effects are protective or
pathological is a matter of debate. EndoS hydrolysis of the IgG glycan has profound effects on IgG effector
functions, such as complement activation and Fc receptor binding, suggesting that the enzyme could be used as
an immunomodulatory therapeutic agent against IgG-mediated diseases. We demonstrate here that EndoS has a
protective effect in myelin oligodendrocyte glycoprotein peptide amino acid 35–55 (MOG35-55)-induced EAE,
a chronic neuroinflammatory demyelinating disorder of the central nervous system (CNS) in which humoral
immune responses are thought to play only a minor role. EndoS treatment in chronic MOG35-55-EAE did not impair
encephalitogenic T cell priming and recruitment into the CNS of mice, consistent with a primary role of EndoS in
controlling IgG effector functions. In contrast, reduced EAE severity coincided with poor serum complement
activation and deposition within the spinal cord, suggesting that EndoS treatment impairs B cell effector function.
These results identify EndoS as a potential therapeutic agent against antibody-mediated CNS autoimmune
disorders.
Introduction
Multiple sclerosis (MS) is a chronic inflammatory dis-
ease of the central nervous system (CNS) characterized
by immune cell infiltration into the white matter,
which in turn produces demyelination, axonal damage,
and the neuronal loss that is considered the main
cause of permanent neurological deficits. The concept
of MS as a purely T-cell-driven autoimmune disease
has been challenged by recent studies indicating an
important role for B cells in the pathogenesis of the
disease [1]. Several key findings suggest a pathogenic
role for B cells and antibodies in MS, mainly in associ-
ation with antibody deposition and complement activa-
tion. Intrathecal immunoglobulin G (IgG) synthesis
and oligoclonal bands are found in more than 90% of
MS patients [2], clonally expanded B cells accumulate
in chronic MS lesions and in the CSF of MS patients
[3], and B-cell follicle-like structures in the meninges
of patients have been identified by histopathology [4].
The results of histopathological analyses indicate that
antibodies might have an important role in plaque ini-
tiation and demyelination in patients with established
MS [5,6]. While the antigen target of these antibodies
has yet to be identified [7-11], the presence of intra-
thecal anti-myelin Ig has been associated with rapid
disease progression [1,12].
Experimental autoimmune encephalomyelitis (EAE) in
mice closely mimics the inflammatory infiltration,
neurological paralytic symptoms, and demyelination
observed in MS. In recent studies, the EAE model has
been critical in dissecting the different roles that B cells
play in the regulation of MS, and has led to new
insights into B cell functions in human pathogenesis
and a focus on the development of B cell therapeutics.
B cell depletion therapy has recently been examined in
EAE induced by myelin oligodendrocyte glycoprotein
amino acid 35–55 (MOG35-55), and confirmed that both
protective and pathological B cell functions markedly
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influence the course of disease [13-16]. Previous studies
indicated that congenitally B cell-deficient mice and
CD19-deficient mice with reduced B cell function de-
velop a severe non-remitting form of MOG35-55-
induced EAE [17], suggesting a regulatory role for B
cells, most likely in association with the production of
IL-10 [14,17]. However, in the MOG35-55-induced EAE
mouse model, an accumulating body of evidence also
indicates a possible contribution of myelin-reactive anti-
bodies to EAE pathogenesis [18]. First, the transfer of
anti-MOG serum from MOG35-55-immunized mice has
been demonstrated to increase the severity of EAE in
wild-type (WT) mice [19]; second, significant positive
correlations were established between anti-MOG35-55
antibody levels and clinical scores, leukocyte infiltration
and reactive astrocytosis in the spinal cord of an animal
model of EAE achieved with a multiple MOG35-55
peptide [20]; and third, mice immunized with
MOG35-55 peptides developed significant serum levels
of anti-MOG antibodies coinciding with clinical EAE
severity [21]. These studies imply that MOG peptide-
specific antibodies may be pathogenic in this strain,
as appears to be the case in several mouse and rat
strains [22].
The capacity of anti-MOG antibodies to contribute
to an ongoing CNS inflammatory and demyelinating
response has been previously demonstrated in models
of antibody-augmented EAE [23-26]. However, how such
autoantibodies might mediate tissue destruction and de-
myelination in EAE remains a subject of intense debate
[27]. Traditionally, pathogenic antibodies or autoanti-
bodies have been implicated in MS through their ability
to mediate their effector function, either via recruitment
of the classical complement cascade or through activa-
tory Fc receptor (FcγR)-mediated antibody-directed cell-
mediated cytotoxicity (ADCC) [27]. The presence of
deposited IgG around the borders of actively demyelinat-
ing MS plaques correlates with the presence of activated
complement fragments and complexes [5,28,29] and
antibodies bound to fragment of myelin within phago-
cytic cells are found at the sites of demyelination [30,31].
In EAE, the role of complement and Fc receptors in dis-
ease pathogenesis remains unclear. Although demyelin-
ation was found to be augmented in brains and spinal
cords of transgenic mice engineered to produce
increased levels of anti-MOG antibodies [26], experi-
ments demonstrated that complement has little or no
involvement in the autoantibody-mediated pathology,
but that the mechanism for exacerbation involved Fc-
mediated effects [32]. However, other data indicate that
inoculation of anti-MOG antibodies drastically increases
clinical MOG35-55-induced EAE in an activatory FcγR-
independent yet complement-dependent fashion [33],
and that in the Lewis rats, the demyelination potential of
MOG-specific antibodies has been shown to correlate
with complement-binding ability [34]. The role of com-
plement activation in MOG35-55-induced EAE has been
debated. While complement-deficient mice [35,36] or
expression of the complement inhibitor sCrry attenuates
EAE [37], other data indicate that key components of
the complement system, such as C1q, C3, C4, and C5a,
may not be involved in MOG35-55-induced EAE patho-
genesis [33,36,38,39].
Regarding the role of autoantibodies in various auto-
immune conditions, novel therapeutic agents that directly
target pathogenic antibodies have recently been success-
fully developed. The IgG-degrading enzyme of Streptococ-
cus pyogenes (IdeS) prevented an antibody-induced
relapse in mice that had chronic arthritis, and delayed the
onset and reduced the severity of experimental collagen-
induced arthritis (CIA) [40]. Like IdeS, EndoS from
Streptococcus pyogenes is an immunomodulating enzyme
that specifically hydrolyzes glycans from human IgG, and
thereby affects antibody effector functions. EndoS has re-
cently been demonstrated as an attractive treatment in
autoantibody-mediated autoimmune disease mouse mod-
els of CIA [41], lethal IgG-driven immune thrombocyto-
penic purpura (ITP), autoimmune hemolysis [42,43], and
glomerulonephritis [44]. Thus, modulation of IgG glycosy-
lation is a promising strategy to interfere with
autoantibody-mediated inflammatory processes, such as
those that may take place during the pathogenesis of MS
or its animal model, EAE.
In the present study, we evaluated the importance of
glycosylation of the IgG molecule by EndoS treatment in
MOG35-55-induced EAE, the most commonly used
model to study the efficacy of potential drugs for the
treatment of MS. In this chronic demyelinating disease
of the CNS we previously showed that specific anti-
bodies against MOG and nucleic acids (RNA and
ssDNA) paralleled disease progression. Here, we
observed that IgG deglycosylation by EndoS treatment
attenuates MOG35-55-induced EAE development in WT
mice but not in B-cell-deficient mice, suggesting that
antibodies aggravate the clinical course in this EAE
model. Histological analysis showed reduced CNS in-
flammatory lesions and demyelination. Data also
revealed significantly reduced serum complement con-
sumption and CNS deposition in EndoS-treated mice
versus untreated mice, suggesting a key role for comple-
ment in EAE progression. Collectively, this study estab-
lishes a role for antibodies in MOG peptide-induced
immune-mediated demyelination, a model largely con-
sidered to be purely T cell-dependent, and suggests that
complement activation may be relevant in the context of
antibody-exacerbated EAE.




Animal experiments described in the present study were
approved by the Ethics Committee for Animal Experi-
mentation of the Faculty of Medicine, University of Gen-
eva, Switzerland (protocol ID number: 1005/3537/3).
Induction of EAE
Acute chronic EAE was induced in 6- to 8-week-old
WT or B cell-deficient (μMT KO) C57BL6J female mice,
as previously reported [45,46]. Briefly, mice were immu-
nized subcutaneously with 100 μg of MOG35-55 peptide
(MEVGWYRSPFSRVVHLYRNGK; AnaSpec, USA)
emulsified in CFA and supplemented with 200 μg of
Mycobacterium tuberculosis strain H37RA (Difco, De-
troit, MI, USA). The mice received intravenous injec-
tions with 300 ng pertussis toxin (Sigma-Aldrich, St
Louis, MO, USA) at the time of immunization and 48 h
later. Clinical disease was scored daily as follows: 0, no
clinical disease; 1, limp tail; 2, impaired righting reflex; 3,
hind limb paralysis; 4, moribund; 5, dead. Severely paral-
yzed mice were afforded easier access to food and water.
Each time point presents the average disease score of
each group. Statistical significance was assessed using an
unpaired Student’s t-test.
EndoS enzyme treatment
EndoS was recombinantly expressed in E. coli and puri-
fied as previously described [47]. EndoS treatment
(intravenous, 20 μg) was initiated 1 day before disease
induction, before disease onset (day 7), and during the
acute phase of the disease (day 14). Control animals
received placebo (PBS) injections.
Analysis of IgG glycan hydrolysis
Mice were bled (tail) on day 1 before immunization, and
on days 7 and 14 after immunization. Serum was isolated
after coagulation and centrifugation (15 min at 3000 g)
and kept frozen at −20°C until use. Purification of total
IgG in plasma was performed using protein G Sepharose
according to the manufacturer’s instructions (GE Health-
care Biosciences). Purified IgG was separated using 10%
SDS-PAGE and stained with Coomassie blue (total pro-
tein stain), or electroblotted onto polyvinylidene difluoride
(PVDF) membranes (immobilon-P; Millipore, Bedford,
MA, USA). Equal amounts of material were loaded into
each well during SDS-Page analysis. Glycosylated IgG was
detected using 1 μg/mL biotinylated Lens culinaris
agglutinin-A (LCA) lectin and 1 μg/mL of streptavidin-
horseradish peroxidase (Vector Laboratories, Burlingame,
CA, USA) and SuperSignal West Pico peroxidase sub-
strate (Pierce, Rockford, IL, USA). Membranes were ana-
lyzed using a Chemidoc XRS imaging system and
Quantity One image analysis software (Bio-Rad, Hercules,
CA, USA).
Serological assay
Serum levels of total IgG were determined by ELISA as
described previously [21]. IgG results are expressed in
μg/mL by referring to a standard curve obtained using a
mouse serum with known IgG concentrations (Miles
Laboratories).
Isolation of CNS-infiltrating mononuclear cells
Mice were anesthetized with sodium thiopental and
perfused through the left ventricle with cold PBS until
the effluent ran clear. Spinal cords were extruded by
flushing the vertebral canal with cold PBS, rinsed in
PBS, and minced with a scalpel blade. The spinal
cords were forced through 100-mesh stainless steel
screens (Falcon, BD Biosciences) to obtain a single-cell
suspension in HBSS containing 300 U/mL per cord of
type IV clostridial collagenase (Sigma), and were then
incubated for 1 h (37°C). The spinal cord homogenate
was resuspended in 30% Percoll (Sigma) and underlaid
with 70% Percoll. The gradients were centrifuged at
500 g at 24°C for 20 min. CNS mononuclear cells were
collected from the 30%/70% interface and were washed
and resuspended in RPMI 1640 medium (Invitrogen)
supplemented with 2 mM L-glutamine, 25 mM
HEPES, 100 U/mL penicillin, 100 μg/mL streptomycin,
2-mercaptoethanol (2-ME), and 10% fetal calf serum
(FCS) (all supplements from Invitrogen). Typical recov-
ery yielded from 5× 105 to 1 × 106 cells per spinal cord.
Isolation of bone marrow cells
Bone marrow cell suspensions were isolated by flushing
the femurs and tibias harvested from EndoS- and PBS-
treated mice at peak disease. Bone marrow cells were
resuspended in complete RPMI 1640 medium (Invitro-
gen) supplemented with 2 mM L-glutamine, 25 mM
HEPES, 100 U/mL penicillin, 100 μg/mL streptomycin,
2-ME, and 10% FCS (all supplements from Invitrogen).
Spleen cell proliferation assay
Splenocyte cell suspensions were isolated from MOG35-55-
immunized mice at day 22 by homogenizing spleens
through a cell strainer (70 μm Nylon, FalconW) and remov-
ing red blood cells with ACK lysing buffer (BioWhittaker,
Walkersville, MD, USA). Splenocytes from six separate
mice from the same group were plated in triplicate in
96-well round bottom plates at 2 × 105 cells/well in
200 μL complete RPMI 1640 medium (Invitrogen) sup-
plemented with 2 mM L-glutamine, 25 mM HEPES,
100 U/mL penicillin, 100 μg/mL streptomycin, 2-ME,
and 10% FCS (all supplements from Invitrogen) con-
taining either 0 to 50 μg/mL of MOG35-55 or CpG
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(2 μg/mL) and cultured at 37°C, 5% CO2 for 72 h. Pro-
liferation was measured by incorporation of 3H-
methylthymidine (1 μCi/well) during the last 16 h of
culture using a filtermate harvester (Packard Instrument
Co.) and a 1450 microbeta liquid scintillation counter
(PerkinElmer). Results were determined as mean ± SD
from triplicate cultures.
Immunologic markers and flow cytometry
Cells from spleens, bone marrow, and spinal cords were
incubated for 30 min at 4°C with FITC, PE, PerCP-Cy5,
or APC fluorochromes conjugated with: CD4, CD8,
CD11c, CD11b, CD138, B220, CD69, and CD44. To
block non-specific Fc-mediated interactions, cells were
incubated in blocking solution (PBS with 1% FCS) for
20 min on ice prior to staining. Samples were run
through a FACS Calibur flow cytometer (Becton Dickin-
son) with standard equipment. Flow cytometry acquisi-
tions were analyzed using FlowJo analysis software
(Version 9.3.2).
Histopathology and immunostaining
Spinal cords at peak of disease (day 22) obtained from
transcardially perfused mice (4% paraformaldehyde) were
embedded in paraffin (n= 4 to 6 animals per experimen-
tal group). Paraffin-embedded blocks were cut into 5-μm
thick sections and stained with hematoxylin-eosin (HE)
to assess inflammation or luxol fast blue/periodic acid
Shiff stain (LFB/PAS) to assess the degree of demyelin-
ation. Quantification was performed by examining five
tranverse sections from the cervical to thoracic spinal
cord per mouse, as described previously [48].
For immunohistochemistry, endogenous peroxidases
(PBS/3% hydrogen peroxide) were inactivated and unspe-
cific binding was blocked (PBS/10% FCS), followed by
incubation with rabbit polyclonal anti-mouse C9 primary
antibodies (provided by Dr M Collin, University of Swe-
den). Bound primary antibodies were visualized using an
avidin-biotin technique with 3,3′-diaminobenzidine as
chromogens (hemalaun counterstaining of nuclei). No
significant staining was detected in slides incubated with
control rabbit IgG. Numbers of C9-positive deposits
within spinal cord lesions/spinal cord white matter (over
an area of at least 150 μm×150 μm per animal) were
expressed as C9 density per μm2 (density index). Rabbit
polyclonal anti-mouse C9 primary antibodies were used
to perform the immunofluorescent double staining. The
distribution of the primary antibodies was visualized
using anti-rabbit IgG secondary antibody conjugated to
the rhodamine fluorochrome. DAPI stain was applied to
visualize cell nuclei. For negative controls, the primary
antibody was replaced with the appropriate non-immune
serum. To control for cross-reactivity in double
immunofluorescence, sections were incubated with sec-
ondary antibody only.
Western blotting
Spinal cords from EndoS-treated mice and control PBS-
treated C57BL6J mice were homogenized using a poly-
tron in lysis buffer (50 mM Tris–HCl, pH 7.5, 250 mM
NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM DTT) con-
taining complete protease inhibitors (Roche) and incu-
bated 30 min on ice. Lysates were sonicated and clarified
by centrifugation. Protein concentration of the different
lysates was determined using Bradford analyses. Aliquots
containing equal amounts (20 μg) of total protein or
serum were heated to 90°C for 5 min in SDS-sample
buffer containing 5% 2-ME (Sigma, Chicago, IL, USA),
transferred to a 7.5-12.5% SDS-polyacrylamide gel and
blotted on an Immobilon-P PVDF membrane (Millipore,
Bedford, MA, USA). After blotting of the proteins, the
blocking and antibody incubation steps were performed
in BPS containing 5% non-fat milk and 0.1% Tween 20
(Sigma). Complement C1q, C3 (in-house made by Dr S
Izui, University of Geneva, Switzerland), and C9 (pro-
vided by Dr M Collin, Lund University, Sweden) were
detected by incubating PVDF membranes 2 h at room
temperature in buffer containing properly diluted goat
anti-mouse anti-C1q and anti-C3 antibodies, and rabbit
anti-mouse anti-C9 antibody. Binding of the primary
antibody was detected using a peroxidase-conjugated
secondary antibody to rabbit IgG (Jackson ImmunoRe-
search labs, West Grove, PA, USA). After washing,
positive bands were visualized using chemiluminescence
(Supersignal; Pierce, Rockford, IL, USA). Relative protein
expression (mean of n= 3 animals ± s.e.m.) was quanti-
fied using Image J software (NIH).
Statistical analysis
Data are expressed as mean± s.e.m. and were analyzed
by unpaired two-tailed Student’s t-test, using Graphpad
Prism 4.01 for Windows (Graphpad Software, San Diego,
CA, USA). P values ≤0.05 were considered statistically
significant.
Results
EndoS treatment ameliorates MOG35-55-induced EAE in
wild-type (not B cell-deficient) mice
To evaluate the effect of IgG hydrolysis on MOG35-55-
induced EAE in C57BL/6 mice, we administered
EndoS (20 μg) (n= 11) or PBS (n= 10) by subcutane-
ous injection to WT and B cell-deficient mice (μMT
KO) 1 day prior to MOG-immunization, before disease
onset (day 7), and during the acute disease phase (day
14) (Figure 1A). PBS-treated WT mice developed se-
vere, chronic, progressive EAE, while disease severity
was significantly diminished in WT mice treated with
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EndoS (Figure 1B, left panel). In WT mice, EndoS
treatment alleviated the severity of EAE during the
acute phase (day 15 post-immunization) and impeded
the full development of EAE during the chronic phase
(from day 22 to 32 post-immunization) even though
treatment was discontinued (Figure 1B). In contrast to
WT mice, the positive treatment effect of EndoS in
EAE was abrogated in μMT KO mice, confirming that
the beneficial effect of EndoS in MOG35-55-induced
EAE requires B cells or B cell products (Figure 1B,
right panel).
EndoS suppresses pathological signs of EAE
Consistent with the clinical finding, histological examin-
ation of CNS tissues revealed a significant pathological
difference between EndoS- and PBS-treated WT mice at
the disease peak (Figure 1C). Figure 1D and 1E depict in-
flammation and demyelination scores from WT mice that
received PBS or EndoS and were sacrificed on day 22
post-immunization. In PBS-treated WT mice, multiple in-
flammatory foci were observed in the white matter of the
spinal cord, together with a high degree of demyelination.
By contrast, significantly fewer inflammatory lesions and
Figure 1 EndoS treatment ameliorates clinical and histological MOG35-55-induced EAE. (A) A schematic representation of the experimental
setup. (B) MOG35-55-induced EAE is inhibited in WT mice, but not in B cell-deficient (μMT KO) mice, treated with EndoS; EAE scores were
determined daily after disease onset in EndoS-treated mice (triangles; n= 11) and PBS-treated controls (squares; n= 10). Data are presented as
mean EAE score ± s.e.m. A significant statistical difference between the two groups of WT mice is observed from peak disease (day 20) to chronic
phase (day 30). Data are representative of three individual experiments. (**P< 0.01). (C) Representative images of paraffin-embedded spinal cord
sections at peak disease (day 22) of indicated groups stained for hematoxylin and eosin (H&E) or Luxol fast blue/Periodic acid Shiff stain (LFB/PAS)
(magnification 200x) are shown. Five sections of spinal cord per mouse (n= 6 for EndoS-treated mice; n= 4 for PBS-treated WT mice) were
analyzed, and the number of (D) inflammatory lesions and (E) extent of demyelination per spinal cord section are presented as histograms. Error
bars represent the mean± s.e.m. **P< 0.01 by Student’s t-test.
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little demyelination were detected in EndoS-treated WT
mice.
Endoglycosidase treatment efficiently hydrolyzes IgG
glycans in vivo in EAE mice
To investigate the IgG glycan-hydrolyzing activity of
EndoS in the circulation of live animals, C57BL6/J WT
mice were intravenously injected three times (on days 0, 7,
and 14) with PBS or 20 μg of EndoS, and serum IgG sam-
ples (drawn on days 1, 8, 15, and 25) were analyzed for
glycosylation status using sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) and lectin blot
analyses using Lens culinaris agglutinin-A (LCA blots).
We first demonstrated that systemic EndoS treatment did
not affect IgG antibody titers during the acute and chronic
phases of EAE (Figure 2A). As previously reported [21],
we observed that IgG levels tightly coincided with
increased disease severity, reaching 6.56± 0.5 mg/mL
(mean± s.e.m.) at day 15 and 8.59± 0.53 mg/mL at day 25
post-immunization, compared with 1.516±0.28 mg/mL
before disease onset in PBS-treated mice (P<0.0001,
Student’s t-test) (Figure 2A). One day after EndoS injec-
tion, the apparent molecular mass of the serum IgG heavy
chain from EndoS-treated mice revealed a complete shift
toward an approximate 3-kDa smaller protein band, com-
pared with fully glycosylated intact mouse IgG from PBS-
treated mice (Figure 2B, stain blot). The apparent lack of
correlation between serum IgG levels (Figure 2A) and the
heavy chain signal (Figure 2B, stain blot) is likely to re-
flect the different sensitivities of the two assays. Lectin
blot analysis revealed that the serum IgG heavy chain
carbohydrate signal was abolished one day after EndoS
injection, further confirming complete IgG glycan hy-
drolysis (Figure 2B, LCA blot). The IgG glycan hydrolysis
patterns were nearly identical after injections 1 and 2,
compared with mice that had not previously been
exposed to EndoS (Figure 2B), with the exception of one
animal that exhibited partial hydrolysis of IgG by EndoS
on day 8.
EndoS treatment does not influence peripheral or central
immune cell function during EAE
Considering the fact that CD4+ T cells are initiators of
EAE and drivers of neuro-immune degeneration in the
CNS, we investigated whether EndoS treatment would
interfere with their cellular functions. We observed that
EndoS treatment did not block the T-cell recall re-
sponse to the encephalitogenic peptide MOG35-55, sug-
gesting that EndoS had no impact on peripheral
priming of MOG-specific autoreactive T cells
(Figure 3A). In support of this assumption, we observed
no difference in T cell (CD4+ and CD8+) peripheral fre-
quency (Figure 3B) or recruitment to the CNS between
PBS- and EndoS-treated EAE mice (Figure 3C). Like-
wise, CpG-dependent B cell proliferation (Figure 3D),
peripheral frequency of CD44+ or CD69+ activated B
cells (Figure 3B), and B cell recruitment into the CNS
(Figure 3C) were not affected by EndoS treatment. In
addition, we did not observe any difference in the per-
ipheral or CNS frequency of myeloid cells, such as
macrophages (CD11b+) and dendritic cells (CD11c+),
prominent constituents of neuroinflammatory infiltrates
in the CNS during EAE that have the capacity to acti-
vate T cells (Figure 3B,C). Finally, EndoS treatment did
not affect the frequency or activation status of immune
cells in the bone marrow (Figure 3E).
EndoS treatment impairs IgG-dependent complement
activation and consumption during MOG35-55-induced
EAE
To determine whether the mechanism by which EndoS
protection involves the modulation of complement acti-
vation, we studied changes in complement component
(C1q, C3, and C9) consumption in EndoS-treated and
untreated WT mice by SDS-PAGE analysis at different
Figure 2 Endoglycosidase treatment has a profound effect on
IgG glycan hydrolysis in vivo. (A) Total serum IgG levels isolated
from EndoS-treated WT mice (n= 6) and PBS-treated treated WT
mice (n= 4) at the indicated time after immunization were
determined by ELISA. (B) SDS-PAGE Coomassie Blue staining (stain)
and lectin blot analysis (LCA) of purified IgG from serum samples
drawn from three representative PBS- or EndoS-treated WT mice at
indicated times after intravenous injection of 20 μg EndoS or PBS (1
and 8 days).
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stages of the disease progression. As previously reported,
EndoS hydrolysis of IgG glycan decreased serum com-
plement activation as early as day 15 post-immunization
in MOG35-55-induced EAE mice (Figure 4A,B). EndoS
treatment had no effect on serum complement con-
sumption at day 8 post-immunization, further confirm-
ing the absence of complement-activating IgG antibodies
(Figure 2A) at the onset of EAE.
Complement component deposition is reduced in the
CNS by EndoS in EAE mice
To investigate whether EndoS treatment influences CNS
complement deposition during MOG35-55-induced EAE,
spinal cords from EndoS- and PBS-treated mice were
examined at day 22 post-immunization (peak disease) for
immunohistochemical detection of complement compo-
nent C9. We observed a significant reduction of C9
Figure 3 EndoS treatment does not limit T cell activation, B cell activation, or CNS recruitment of lymphoid or myeloid cells. (A) EndoS
has no impact on peripheral T cell priming or recall responses of spleen cells in response to MOG35-55 peptide, as measured using a
3 H-
thymidine incorporation assay. EndoS treatment does not influence the (B) peripheral frequency or activation or (C) CNS (spinal cord) infiltration
of important lymphoid and myeloid immune cell populations, as measured (mean± s.e.m.) by flow cytometry analysis of cells isolated from
EndoS-treated mice (n= 6) and PBS-treated mice (n= 4) at day 25 post-immunization. (D) CpG is equally effective in stimulating the proliferation
of splenic B cells from PBS- or EndoS-treated mice, as determined by 3 H-thymidine incorporation after 3 days of culture. (E) EndoS treatment
does not affect the frequency or activation status of immune cells in the bone marrow.
Figure 4 EndoS inhibits peripheral complement activation in EAE mice. (A) Serum complement activation or consumption of complement
components C1q, C3, and C9 was evaluated by SDS-PAGE analysis of sera from EndoS- and PBS- treated WT mice (n= 3 per group) at the
indicated time after immunization. (B) Relative serum expression of complement components C1q, C3, and C9 (n= 3 independent mice
per group) was expressed as arbitrary units of density of bands (intensity/mm2).
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deposit density in EndoS-treated mice (0.58±0.06× 103/
μm2, n=35 lesions) compared with PBS-treated control
mice (2.05±0.16× 103/μm2, n=36 lesions) (Figure 5A,B).
Consistent with this observation and peripheral C9 com-
plement activation, C9 was detected by western blotting
and immunofluorescence microscopy in spinal cord from
PBS-treated, but not EndoS-treated, WT mice (Figure 5C,
D). These data suggest both a role for C9 in brain inflam-
mation during MOG35-55-induced EAE, and a possible in-
hibitory mechanism of action of EndoS.
Discussion
EAE shares clinical and histopathological similarities
with MS and serves as the most widely used animal
model for the disease. Data from MS patients and EAE
studies support a role for B cells/antibodies in the dis-
ease process. The presence of oligoclonal bands in the
cerebrospinal fluid (CSF) of MS patients, and their
association with a worse prognosis, supports a patho-
genic role for antibodies in CNS autoimmunity [49,50].
Here, we established that enzymatic IgG glycan hydroly-
sis by EndoS attenuates MOG35-55-induced EAE. We
observed no differences in CNS-infiltrating CD4+ T cell
frequencies or activation during EAE, confirming that
EAE protection occurs independently of T cell immun-
ity. Clinical benefit of EndoS treatment in mice was
associated with reduced complement system activation
in the presence of comparable IgG levels between trea-
ted and untreated groups, supporting a profound effect
of IgG glycan on IgG effector functions. Overall, our
data strengthen the importance of antibodies in
MOG35-55-induced EAE, a model of CNS inflammation
that is considered less dependent upon B cells and
humoral immune responses, and also suggest that the
EndoS enzyme could be used as an immunomodula-
tory therapeutic agent against IgG-mediated CNS auto-
immune diseases.
Although the role of CD4+ T cells in EAE/MS initiation
is widely accepted, the role of B cells and antibodies in
disease pathogenesis remains unclear. Several previous
studies have however provided cumulative evidence for
an active role of anti-myelin antibodies in inducing de-
myelination [7,8,11]. In EAE, although anti-MOG anti-
bodies cannot trigger CNS inflammation on their own,
they strongly augment T cell-initiated and macrophage-
enhanced demyelination, and may augment disease sever-
ity [51,52]. Several studies indicate that the demyelinating
activity of myelin-specific antibodies is related to their
ability to fix complement [53]. Other roles for B cells in
MS/EAE pathogenesis include directing the polarization,
activation, or specificity of disease-relevant T cells [13,54],
production of pro- and anti-inflammatory cytokines, and
potentiation of remyelination [55].
Early studies in the C57BL/6 mouse EAE model have
indicated that the induction of disease may be B cell-
dependent, depending on the source and nature of the
MOG immunogen. Induction of EAE after immunization
with MOG35-55 [17,25] or recombinant MOG (rMOG)
protein from mouse or rat [17,56] but not human [25,56]
was shown to be B cell-independent. However, recent B
cell depletion studies and other experimental paradigms
have demonstrated both protective and pathogenic roles
for B cells in EAE models in which they were previously
considered to contribute only marginally to disease
pathogenesis [13,14,17]. Previous data from the EAE
models indicated that the role of antibodies in the disease
process might differ based on the model employed
[25,56]. While immunization with rodent or human
rMOG [56] or MOG35-55 [57] leads to the development
of antibodies that bind mouse MOG, reports indicate that
only MOG-specific antibodies generated in response to
human rMOG are pathogenic [25]. However, recent
Figure 5 High levels of C9 are detected in the spinal cord of
PBS-treated EAE mouse models, but absent from EAE mice
treated with EndoS. (A) Representative C9 immunostaining
(brown) in the spinal cord of WT MOG35-55 peptide-induced EAE
mice at day 22 post-immunization (disease peak) (magnification
200x). (B) EndoS treatment significantly lowered the density of C9
deposits in mouse spinal cord (n= 4). ***, P ≤0.001 by Student’s
t-test. (C) A representative western blot of spinal cord extracts from
EndoS- and PBS-treated mice (n= 3 per group) probed with the
anti-C9 antibody. Anti-α-Actin served as the loading control. (D)
Complement C9 deposition in the CNS is strongly reduced by
EndoS treatment in EAE mice. Double-label immunofluorescence
microscopy demonstrated that complement component C9
(pink-purple) is deposited in the CNS of PBS-treated (but not
EndoS-treated) mice. Cell nuclei were counterstained with DAPI
(blue).
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cumulative data support a pathogenic role for antibodies
in MOG35-55-induced EAE in C57BL/6 mice [18-21].
In this study, we report that specific IgG glycan hy-
drolysis by EndoS attenuates MOG35-55-induced EAE in-
dependent of T cell immunity. Importantly, we observed
a clear association between the appearance of serum
antibodies and the occurrence of clinical EAE signs. In
this context, we found that the beneficial effect of EndoS
in neutralizing the effector functions of antibodies was
only evident shortly after disease onset, when myelin-
specific antibodies are thought to contribute to disease
progression. Additionally, our findings demonstrating a
reduction of complement activation, and in particular
C9, after EndoS administration are strongly suggestive of
a role for this system in the development and clinical ex-
pression of MOG35-55-induced EAE. In addition to the
complement system, it is also conceivable that EndoS
might interfere with a function of FcR in antibody-
mediated demyelination [58,59], such as inefficient
ADCC [60]. However, this concept is strongly challenged
by EAE studies indicating that autoantibody-directed de-
myelination depends on complement activation but not
activatory FcγR [33,59] and that the antibody-binding
FcαR units are not required for disease development
[61].
Several reports indicate that complement activation
may play an essential role in the mediation and mainten-
ance of inflammatory reactions and the process of de-
myelination in the CNS [62], particularly in diseases
such as MS and neuromyelitis optica (NMO). Terminal
complement component has been shown in actively de-
myelinating areas of the CNS in MS [5,63], and evidence
exists that complement (specifically, the assembly of the
C5b-9 complex) promotes myelin damage and demyelin-
ation in well myelinated mouse cerebellum cultures [64].
Increased levels of the C5b-9 complex have been
detected in the spinal fluid of MS patients during
relapses [65,66], and these levels have been correlated
with neurological disability. In EAE, several studies have
used experimental manipulations that reduce the activa-
tion of the complement to evaluate its role in disease
pathogenesis. Among others, serum complement deple-
tion with cobra venom factor (CVF) reduced actively
induced acute EAE in rats [62]. Similar to our findings,
CVF and its effect on the complement cascade have
been shown to reduce the severity of EAE-related in-
flammation and demyelination without significantly in-
fluencing certain histopathological concomitants [23,62].
In support of our findings, activation of C9 (the major
component of the cytolytic membrane attack complex)
in EAE is related to myelin injury rather than CNS
inflammation [67].
While our data indicate that reduced complement activa-
tion by EndoS hydrolysis of IgG may account for its clinical
benefit in EAE, recent findings suggest that EndoS-
hydrolyzed human IgG does bind better to FcγRIIb than
non-hydrolyzed IgG under certain circumstances [68]. In
the context of MOG35-55-induced EAE pathogenesis, this
finding might be relevant, as recent evidence suggest that
autoimmune-prone FcγRIIb-deficient mice exhibit more
pronounced MOG35-55-induced EAE disease [60]. Import-
antly, intravenous Ig (IVIG) injection, which is reportedly
therapeutic in MOG35-55-induced EAE [69] and has
exhibited some evidence of efficacy in MS [70], may act
by targeting the low-affinity IgG inhibitory receptor
FcγRIIb [71]. Therefore, one could speculate that EndoS
treatment in MOG35-55-EAE may have a dual anti-
inflammatory activity, both inhibiting the activation of
the complement and shifting the binding of pathogenic
IgG toward the inhibitory action mediated through
FcγRIIb. Although additional studies are needed to test
this hypothesis, it represents a potential additional mech-
anism of action of EndoS that could account for its pro-
tective effects in EAE. Moreover, while data indicate that
EndoS specifically hydrolyzes native IgG (no other sub-
strate has been identified to date) [47], we could not ex-
clude the possibility that EndoS could cleave glycans
other than those on IgG. Whether IgG deglycosylation
plays a more significant role in a B cell-dependent EAE
model using recombinant MOG protein would therefore
be of specific interest.
The presence of Ig’s and complement activation pro-
ducts in active MS lesions and the efficacy of therapeutic
plasma exchange in some patients provide circumstantial
evidence for the involvement of antibodies in MS
[72,73]. Here, we establish that administration of EndoS,
an enzyme from Streptococcus pyogenes that efficiently
hydrolyzes the functionally important and conserved N-
linked glycan of IgG in vivo, significantly attenuates dis-
ease progression in a model of CNS inflammation and
demyelination. Together with treatment with B cell-
depleting antibodies that target cellular function of B
cells [74], we propose that EndoS-mediated IgG hydroly-
sis may constitute a potential novel therapeutic principle
for the treatment of IgG-driven human CNS autoimmune
diseases such as MS. Reasonable pharmacokinetics of this
enzyme is further ensured by its ability to avoid antibody-
mediated elimination [42] via removal of glycans neces-
sary for the binding of neutralizing antibodies.
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